Начало・Списък с акции・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Затворен

СекторЗдравеопазване

35.58 0.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.65

Максимум

35.79

Ключови измерители
By Trading Economics
Приходи	-2.5M 14M
Продажби	-12M 194M
P/E Средно за сектора	17.077 64.641
EPS	1.76
Марж на печалбата	7.491
Служители	423
EBITDA	-213M 91M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+61.13% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	31M 1.2B
Предишно отваряне	34.87
Предишно затваряне	35.58

Настроения в новините

By Acuity

34%

66%

104 / 340 Класиране в Healthcare

Collegium Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:46 ч. UTC

Collegium Pharmaceutical Inc is trading lower today, continuing a three-session decline. The stock peaked early but has since pulled back.

31.07.2026 г., 20:06 ч. UTC

News

Collegium Pharmaceutical is under scrutiny due to concerns over its financial performance, contributing to a decline in shares during Friday's session.

30.07.2026 г., 20:09 ч. UTC

Collegium Pharmaceutical Inc shares are lower in Thursday's session, with no specific news to explain the decline amid broader market volatility.

29.07.2026 г., 22:01 ч. UTC

Collegium Pharmaceutical Inc is trading higher in after-market hours, continuing a positive trend with gains over four consecutive sessions amid cautious investor sentiment.

28.07.2026 г., 22:01 ч. UTC

Collegium Pharmaceutical Inc shares are lower in after-market hours, continuing a decline from Tuesday's close amid broader market pressures, particularly in Asia.

27.07.2026 г., 19:07 ч. UTC

News

Collegium Pharmaceutical reported first-quarter revenues of $193.5 million, surpassing expectations, while shares are trading higher amid broader strength in the pharmaceutical sector.

24.07.2026 г., 19:46 ч. UTC

Collegium Pharmaceutical Inc shares are lower during Friday's session, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

22.07.2026 г., 20:01 ч. UTC

Collegium Pharmaceutical Inc shares are lower today, continuing a downward trend seen since Tuesday's close, with no specific news identified for the decline.

21.07.2026 г., 20:01 ч. UTC

Collegium Pharmaceutical Inc is trading higher amid a broader market rally, with the Pharmaceuticals sector also gaining momentum. No specific news was identified.

20.07.2026 г., 19:41 ч. UTC

News

Collegium Pharmaceutical plans to move its headquarters to Boston in 2027. Shares are lower amid significant declines in the Pharmaceuticals sub-sector.

Сравнение с други в отрасъла

Ценова промяна

Collegium Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

61.13% нагоре

12-месечна прогноза

Среден 57.33 USD 61.13%

Висок 60 USD

Нисък 56 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Collegium Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Collegium Pharmaceutical Inc през последните 3 месеца.

Настроение

By Acuity

104 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.